Chronic, nonresolving inflammation is a critical factor in the clinical progression of advanced atherosclerotic lesions. In the normal inflammatory response, resolution is mediated by several agonists, among which is the glucocorticoid-regulated protein called annexin A1. The proresolving actions of annexin A1, which are mediated through its receptor N-formyl peptide receptor 2 (FPR2/ALX), can be mimicked by an amino-terminal peptide encompassing amino acids 2-26 (Ac2-26). Collagen IV (Col IV)-targeted nanoparticles (NPs) containing Ac2-26 were evaluated for their therapeutic effect on chronic, advanced atherosclerosis in fat-fed Ldlr −/− mice. When administered to mice with preexisting lesions, Col IV-Ac2-26 NPs were targeted to lesions and led to a marked improvement in key advanced plaque properties, including an increase in the protective collagen layer overlying lesions (which was associated with a decrease in lesional collagenase activity), suppression of oxidative stress, and a decrease in plaque necrosis. In mice lacking FPR2/ALX in myeloid cells, these improvements were not seen. Thus, administration of a resolution-mediating peptide in a targeted NP activates its receptor on myeloid cells to stabilize advanced atherosclerotic lesions. These findings support the concept that defective inflammation resolution plays a role in advanced atherosclerosis, and suggest a new form of therapy.
INTRODUCTION
Atherosclerosis, the disease process responsible for the leading cause of death in the industrialized world, is driven by a chronic, maladaptive inflammatory response (1) . This response is triggered by the persistent and amplified subendothelial retention of apolipoprotein B-containing lipoproteins in focal areas of the arterial tree (2) . The normal inflammatory response is followed by a resolution phase, which is effected by specific lipid and protein mediators that terminate inflammation and promote tissue repair (3, 4) . In this regard, many of the characteristics of clinically dangerous advanced plaques, including thinning of a protective "cap" of subendothelial collagen, oxidative stress, defective clearance of dead cells (efferocytosis), and tissue-damaging necrosis, suggest that this resolution process is defective in these lesions (5, 6) . However, more proof in vivo is needed to support this concept. In addition, cellspecific resolution processes that fail in advanced atherosclerosis need to be identified, and the therapeutic potential of enhancing resolution in this disease remains to be explored.
The therapeutic potential of enhancing resolution in a chronic disease like atherosclerosis could be substantial in that mediators of resolution, unlike anti-inflammatory drugs per se, have a much greater potential to suppress inflammation and promote tissue repair without compromising host defense (7, 8) .
Although atherosclerosis can be treated with low-density lipoprotein (LDL) lowering by statins, cardiovascular disease remains the leading cause of death worldwide (9) . In view of the evidence for defective inflammation resolution in atherosclerosis (5, 6) , proresolving therapy may be able to expand treatment options for cardiovascular disease. To date, mouse studies have shown the benefit of adenoviral interleukin-10 (IL-10) treatment (10) , but systemic delivery of IL-10 would require frequent dosing at a high dose, which is expensive, inconvenient, and potentially dangerous, especially for a chronic condition like atherosclerosis. For example, adverse effects of high-dose systemic recombinant IL-10 therapy in Crohn's disease patients include thrombocytopenia; anemia; proliferation of B cells, CD8 + cytotoxic T cells, natural killer cells, and mast cells; and elevated interferon-g (11, 12) . Moreover, systemic IL-10 can also compromise host defense, which can be avoided by tissue-specific transgenesis in mice (13) .
One class of resolution mediators consists of fatty acid-derived lipids called lipoxins, resolvins, protectins, and maresins, which are collectively referred to as specialized proresolving lipid mediators (3) . Several of these mediators, notably RvE1, have shown benefit in preclinical models of certain chronic inflammatory diseases, including asthma, rheumatoid arthritis, and periodontal disease (14, 15) . In humans, proresolving lipid mediators have shown benefit in dry eye syndrome, a chronic inflammatory disease affecting the ocular surface (www.clinicaltrials.gov; NCT00941018). Another class of proresolving mediators includes proteins such as transforming growth factor-b (TGF-b) and annexin A1 (4). Endogenous annexin A1, a 37-kD protein, mediates inflammation resolution in several disease models, and administration of a 25-amino acid peptide encompassing its pharmacophore N-terminal region, called Ac2-26, can mimic the effects of annexin A1 (16) . Annexin A1 and Ac2-26 bind and activate a specific G protein-coupled receptor (GPCR) called N-formyl peptide receptor 2 (FPR2/ALX) to evoke their protective actions, and intriguingly, this is the same receptor used by two lipid mediators: resolvin D1 (RvD1) and lipoxin A 4 (LXA 4 ) (17) (18) (19) (20) .
We chose the proresolving mediator Ac2-26 because it is a small, stable peptide and can be targeted to atherosclerotic lesions using nanotechnology. Ac2-26 is rapidly cleared from plasma, and so repeated administrations of large amounts of peptide are needed for efficacy (21) .
Although this strategy may be acceptable for the treatment of acute inflammatory conditions, it would be difficult to use in chronic diseases such as atherosclerosis. In an attempt to overcome this problem, we recently encapsulated Ac2-26 in controlled release polymeric nanoparticles (NPs) that are targeted to sites of injury through the addition of a collagen IV (Col IV)-binding peptide (22) . As initial proof of concept, we showed that these Col IV-Ac2-26 NPs accumulated in areas of acute inflammation and tissue injury and enhanced resolution to a much greater extent than free Ac2-26 peptide. However, these acute settings are very different from chronic, nonresolving inflammatory conditions because of the central role of failed resolution in the chronic conditions and the need for prolonged therapy.
In this context, we now report our findings on the application of this strategy to advanced atherosclerosis. Because Col IV is a major component of the vascular basement membrane that becomes exposed at sites of vascular injury and inflammation (23, 24) , we reasoned that Col IV exposure at sites of atherosclerosis would facilitate lesional targeting of the NPs. In mice, we show that Col IV-Ac2-26 NPs home to atherosclerotic lesions and stabilize vulnerable plaques by reducing lesional superoxide and collagenase activity in a myeloid-FPR2/ALXdependent manner. These findings are consistent with the concept that inflammation resolution is defective in advanced atherosclerosis. Further, these findings suggest a new modality to combat inflammation in atherosclerosis in a way that is predicted to compromise the host defense system less than directly targeting inflammatory mediators or their receptors.
RESULTS
Col IV-Ac2-26 NPs home to experimental atherosclerotic lesions The design of the Col IV-Ac2-26 NPs used in this study was based on four principles (22) : (i) long circulating half-life to facilitate localization and plaque accumulation; (ii) small size to facilitate permeation of the endothelium, that is, NPs that are~100 nm or smaller can access the vascular wall by enhanced permeability and retention; (iii) molecular targeting to enhance retention in the plaque; and (iv) controlled, extracellular cargo release to enable the drug to activate its cell surface receptor target at an optimal concentration and for a maximal duration. The NPs were composed of PLGA and PEG, and were conjugated to Ac2-26 peptide ( fig. S1 ). Both the Ac2-26 NPs and control NPs with scrambled peptide were formulated using nanoprecipitation such that the diameter was <100 nm and the surface charge was <−30 mV (fig. S1 , A and D), as described previously (22) . The surface of the NPs was decorated with a Col IV-binding heptapeptide, which we identified previously from a phage display library (23) . Control therapy was Ac2-26 NPs that lacked the Col IV-binding peptide.
To test targeting of atherosclerotic lesions, Ldlr −/− mice were fed the Western diet for 12 weeks to promote atherosclerosis and then injected intravenously with Ac2-26 NPs or Col IV-Ac2-26 NPs conjugated with Alexa 647. Because the NPs were designed to release >95% of the Ac2-26 over 5 days, we chose to harvest the aortic roots, spleens, and livers 5 days after NP infusion. We found that Alexa 647 fluorescence in the aortic root was twofold greater for Col IV-Ac2-26 NPs than for the Ac2-26 NPs, particularly in the subendothelial region (Fig. 1, A and B) . About 70% of the Col IV-Ac2-26 NPs were present in the atherosclerotic lesions relative to spleen and liver, whereas the opposite relative distribution was found for the non-Col IV NPs (Fig. 1B) . Thus, Col IVAc2-26 NPs bind more selectively to atherosclerotic lesions than do nontargeted Ac2-26 NPs.
Col IV-Ac2-26 NPs increase subendothelial collagen in mice with established atherosclerosis To test the efficacy of Col IV-Ac2-26 NPs in advanced atherosclerosis, Ldlr −/− mice were fed a Western diet for 12 weeks, after which Col IVAc2-26 NPs, free Ac2-26, control Col IV-scrambled peptide NPs, and vehicle control (normal saline) were injected intravenously once per week over a 5-week period. Body weights, plasma cholesterol, lipoprotein profiles, and fasting blood glucose were similar between the four groups of mice ( fig. S2 ). Aortic root and brachiocephalic (BCA) lesions were harvested, and their cross sections were analyzed for several hallmarks of advanced plaque progression that are associated with vulnerable plaques in humans (25) . One such hallmark is thinning of a protective layer, or cap, of subendothelial collagen that overlies the necrotic center of advanced lesions.
As expected for Ldlr −/− mice fed the Western diet for 17 weeks, the aortic root lesions of the control cohort had relatively thin layers of subendothelial collagen ( Fig. 2A) . In contrast, this collagen layer was significantly thicker in the Col IV-Ac2-26 NP-treated group compared with the other groups, and comparison of 12 weeks (before treatment) versus 17 weeks indicated that this effect of the Col IV-Ac2-26 NPs was associated with an increase in cap thickness during the 5-week treatment period. In the spleen and liver, the amount of collagen and the expression of the fibrosis marker a-actin were unaffected by Col IV-Ac2-26 NPs ( fig. S3 ), suggesting that the increase in collagen in the aortic root was a targeted process and not associated with potentially adverse fibrosis in other tissues. Overall lesion area and the numbers of lesional macrophages and smooth muscle cells (SMCs) were similar among all treatment groups ( fig. S4 , A to C), consistent with a primary effect of the Col IV-Ac2-26 NPs on the critical plaque parameter of lesion remodeling.
One likely cause of fibrous cap thinning is increased activity of collagendegrading metalloproteinases, which are secreted by inflammatory macrophages (26, 27) . Therefore, we tested whether the increase in fibrous cap thickness in the aortic root lesions of Col IV-Ac2-26 NP-treated mice was associated with a decrease in lesional collagenase activity. Using lesional cross sections incubated with a fluorescently labeled substrate that increases in fluorescence upon hydrolysis, we found that collagenase activity was significantly lower in the lesions of Col IV-Ac2-26 NP-treated mice (Fig. 2B ).
Another possible mechanism for increased fibrous cap thickness could be enhanced collagen biosynthesis. Consistent with this possibility was the finding that the lesions of Col IV-Ac2-26 NP-treated mice had significantly enhanced Col3a1 mRNA (Fig. 2C ). These combined data are consistent with the idea that Col IV-Ac2-26 NPs increase fibrous cap thickness by a combination of decreasing cap degradation and increasing cap synthesis.
Col IV-Ac2-26 NPs suppress superoxide and increase IL-10 in atherosclerotic lesions Hydrogen peroxide and other reactive oxygen intermediates (ROIs) are generated during the acute inflammatory response to kill pathogens, but excessive ROIs can damage host tissues. Hence, a key function of the resolution response is to terminate the production of ROIs (28) . One of the signs of defective inflammation resolution in advanced atherosclerosis is excessive oxidative stress (29, 30) . Using aortic root sections incubated with dihydroethidium (DHE), a fluorescent probe that detects superoxide in tissues, we observed that lesions of Col IV-Ac2-26 NP-treated mice had significantly less superoxide than those of the other control groups (Fig. 3A) . Superoxide was not decreased in the spleen and liver of Col IV-Ac2-26 NP-treated mice, further suggesting a tissue-specific action of these NPs at the aortic root ( fig. S3 ).
To further probe the mechanism of the decrease in superoxide by Ac2-26, we studied primary macrophages incubated with an oxysterol found in atherosclerotic lesions, 7-ketocholesterol (7KC), which is known to induce Nox2-dependent oxidative stress in macrophages (31) . Consistent with the in vivo lesional data, Ac2-26 significantly blocked 7KC-induced reactive oxygen species (ROS) in a FPR2/ALX-dependent manner ( fig. S5A) . A parallel set of experiments revealed that 7KC-induced ROS was markedly decreased in macrophages from Nox2 −/− mice, and Ac2-26 did not further lower ROS in these mutant macrophages ( fig. S5B ). Although these data are difficult to interpret given the very low level of ROS in the Nox2 −/− macrophages treated with 7KC alone, it is possible that part of the mechanism of Ac2-26-mediated reduction in ROS is through suppression of 7KC-induced Nox2 activation.
Another source of ROS in atherosclerotic lesional macrophages is mitochondrial oxidative stress (mitoOS), which promotes plaque development by enhancing inflammation in lesions (30) . We therefore investigated whether Col IV-Ac2-26 NPs temper mitoOS in lesions. MitoOS causes oxidative damage to mitochondrial DNA and thus can be assayed by measuring a marker of this process-mitochondrial (nonnuclear) 8-hydroxydeoxyguanosine (8-OHdG); this assay also measures nuclear 8-OHdG, which reflects more global intracellular oxidative stress (30) . Col IV-Ac2-26 NPs significantly decreased both nuclear and nonnuclear 8-OHdG staining in lesional macrophages (Fig. 3 , B and C), suggesting that the treatment tempered both general oxidative stress and mitoOS in lesional macrophages.
An important hallmark of inflammation resolution is increased production of proresolving mediators (32) . We therefore assayed expression of the mRNA for the proresolving cytokine IL-10 and found that it was elevated in the lesions of Col IV-Ac2-26 NP-treated mice (Fig. 3D) . Il10 mRNA was not significantly increased in the spleen or liver of the Col IV-Ac2-26 NP-treated mice, again suggesting a tissuetargeted action of these NPs ( fig. S3 ). 
Mac3
− cells significantly decreased after 17 weeks of Western diet, raising the possibility that a decrease in the level of macrophage FPR2/ALX contributes to defective inflammation in advanced atherosclerosis.
We determined whether the proresolving effects of Col IV-Ac2-26 NPs on atherosclerotic lesions were linked to the known mechanistic basis of Ac2-26 action, that is, binding to and activation of the FPR2/ALX receptor on myeloid-derived cells. Irradiated Ldlr −/− mice were transplanted with bone marrow cells from wild-type (WT) or from Fpr2 −/− mice and then subjected to the NP treatment protocol and lesional analyses as in the previous studies. As with the nontransplant model, lesion area and systemic metabolic parameters were similar among the four groups of mice (figs. S4D and S7). In the WTtransplanted mice (WT→WT), Col IV-Ac2-26 NPs enhanced fibrous cap thickness (Fig. 4A) , similar to what was found in the non-BMT (bone marrow transplant) model. However, this response was blunted in →WT Ac2-26-NP group may reflect a modest, direct action of Ac2-26 on non-bone marrow-derived intimal SMCs, which are known to be a source of collagen in lesions, but this alternate mechanism was not investigated here.
Treatment with Col IV-Ac2-26 NPs also significantly reduced collagenase activity and lesional superoxide in the lesions of WT→WT mice, but not in the lesions of the Fpr2 −/− →WT mice (Fig. 4, B and  C) . Together, these data indicate that the protective actions of Col IV-Ac2-26 NPs were due primarily to activation of their FPR2/ALX receptor on myeloid-derived cells.
Col IV-Ac2-26 NPs decrease lesion area, necrotic area, and oxidative stress in brachiocephalic arterial plaques In mouse models of atherosclerosis, the brachiocephalic artery (BCA) tends to develop advanced necrotic plaques, perhaps consequent to the effects of disturbed blood flow on lesional endothelium (33) . Inspection of the intact BCA, where atherosclerotic lesions appear white, as well as quantitative analysis of lesion cross sections revealed that Col IV-Ac2-26 NPs decreased lesion area and especially necrotic area, where the suppression was about 80% (Fig. 5, A to D) . Indeed, the decrease in lesion area measurement in the BCA can be explained mostly by the marked decrease in necrotic area, because in these lesions, the necrotic area represents a substantial portion (~40%) of the total lesion area. We also quantified lesional intercellular adhesion molecule-1 (ICAM) immunostaining, a marker of inflamed vasculature, and found a substantial decrease in the cohort treated with Col IV-Ac2-26 NPs compared with animals treated with the scrambled control peptide (Fig. 5E) . Finally, as with the aortic root, lesional DHE staining was markedly less in the BCA of Col IV-Ac2-26 NP-treated mice (Fig. 5F ).
DISCUSSION
The goal of this study was to therapeutically target defective inflammation resolution in advanced atherosclerotic plaques and thereby suppress plaque progression. To this end, we administered a mediator of inflammation resolution, Ac2-26, in an NP form, specifically targeting Col IV in atherosclerotic plaques. We demonstrated thickening of the plaque fibrous cap, suppression of lesional superoxide, and, in BCA lesions, a decrease in plaque necrosis. Each of these improvements is consistent with improved resolution of inflammation.
Previous studies have used various genetic manipulations to overexpress a proresolving cytokine, IL-10, in mouse models of atherosclerosis. In one such study, Ldlr −/− mice were transplanted with the bone marrow of IL-10 transgenic mice, and aortic root plaque complexity was decreased in these chimeric mice compared with lesions of control WT→Ldlr −/− mice (34). Despite these promising findings, whole-organism genetic manipulation is not a therapeutic option for humans, and the use of cytokines for atherosclerosis would need to be adapted to a therapeutic approach. The Col IV-Ac2-26 NPs in this study led to an increase in Il10 mRNA in lesions, suggesting that its benefits may, in part, be mediated by IL-10. Ac2-26 targets the receptor FPR2/ALX, and a key attribute of such ligands is that they dampen excessive inflammation without compromising host defense (3). This is critical because therapies that target inflammatory cytokines often compromise host defense against pathogens, particularly when they are administered over a long period of time (8) . Thus, therapeutics that enhance resolution might have a better benefit/risk ratio than currently available anti-inflammatory drugs, such as anti-TNFa (tumor necrosis factor-a) (8) .
A key set of questions that emerges from this study is related to the molecular and cellular mechanisms that underlie the protective effects of Ac2-26 and FPR2/ALX signaling. For example, the increase in fibrous cap thickness was associated with a decrease in lesional collagenase activity and an increase in Col3a1 expression, but the mechanism and importance of these processes in fibrous cap remodeling remain to be elucidated. Regarding collagen synthesis, annexin A1 can act directly on SMCs (35) . However, the results of the Fpr2 −/− BMT study raise the possibility that Ac2-26 enhances the production of collagen by lesional SMCs by first inducing macrophages to secrete TGF-b, which is a profibrotic mediator that can promote plaque stabilization (36) . Another question is how the intralesional location of collagen accrual is regulated by proresolving mediators. Although collagen near the lumen in advanced plaques is beneficial to prevent rupture, collagen accrual in other parts of the lesions may promote detrimental vascular stiffness (37) . Other examples of mechanistic questions for future investigation include how Ac2-26 quenches oxidative stress and how it suppresses plaque necrosis (38) (39) (40) . Finally, another FPR2/ALX ligand, RvD1, can decrease the ratio of leukotriene to lipoxin in leukocytes in acute peritonitis (41, 42) ; if this process occurs in lesional macrophages, it could provide a mechanism for decreased influx of inflammatory leukocytes, because leukotriene B 4 (LTB 4 ) has chemoattractant activity. Moreover, if lesional LXA 4 levels were increased by Col IV-Ac2-26 NPs, this may amplify the Ac2-26 effect, because LXA 4 activates the FPR2/ALX receptor and stimulates annexin A1 mobilization from neutrophils (31) .
This study raises the question as to why resolution becomes defective as lesions progress. There is evidence that endogenous resolution pathways are operational in earlier lesions, notably those activated by IL-10 and 12/15-lipoxygenase (LOX)-derived specialized proresolving lipid mediators, such as LXA 4 and RvD1 (5, 43, 44) . Possible explanations for why these and other pathways fail in advanced lesions include defective mediator production, enhanced mediator catabolism, conversion to inactive or proinflammatory compounds, and/or defective resolution receptor signaling. High-fat diet may also suppress the synthesis of proresolving mediators by 12/15-LOX (43) . Furthermore, various specialized proresolving lipid mediators are converted into inactive forms through enzymatic metabolism (45, 46) . Because FPR2/ALX receptor expression decreases as atherosclerosis advances, there is a possibility that therapeutics that target this receptor, such as Col IV-Ac2-26 NPs, are less effective when lesions reach this very advanced stage. However, the therapeutic effects of Col IV-Ac2-26 NPs in mice with advanced atherosclerosis shown here suggest that the residual receptor level is sufficient to mediate beneficial effects, at least when the ligand is presented in a high enough concentration. In contrast, the diminished FPR2/ALX expression during advanced atherosclerosis may not be sufficient for endogenous ligands to mount proresolving pathways, which may be an underlying mechanism contributing to defective resolution in advanced atherosclerosis.
Most atherosclerotic lesions do not progress and do not cause acute coronary syndromes, but those that do progress are responsible for the leading cause of death in the industrialized world: cardiovascular disease. Clinically important, unstable plaques in humans are not necessarily larger, but do have distinct morphological features that promote plaque rupture: larger necrotic cores, thinner fibrous caps, higher oxidative stress, and inflammation (25) . Therefore, a critical goal in this area of research is to identify specific molecular-cellular mechanisms that lead to these plaque features and then, with this knowledge, devise strategies to therapeutically inhibit these processes in an effective and safe manner. Although the initial inflammatory response itself is an important process in plaque progression, directly inhibiting this response in a chronic setting, for example, through anti-cytokine therapy, runs the danger of compromising host defense. On the other hand, defective inflammation resolution accurately defines vulnerable plaque characteristics, and it is amenable to a therapeutic approachtargeted administration of resolution mediators-that is predicted not to compromise host defense (7, 8, 16) .
The experiments herein used one animal model of advanced atherosclerosis and tested a proof-of-concept targeted NP with one type of proresolving mediator. To bring targeted resolution mediator nanotherapeutics to the clinic for patients at high risk for atherothrombotic vascular events, additional confirmatory studies will be needed, including evaluation in more predictive models, such as fat-fed pigs and nonhuman primates. It is plausible that the properties of the NPs including the active proresolving agent will need to be optimized for suitable clinical applications (47) . Although Ac2-26 has provided a useful proof-ofprinciple approach, other types of resolution mediators, including variations on the Ac2-26 peptide itself, may be more potent in promoting plaque resolution. Finally, detailed toxicity studies will be needed to show the safety of both the NP material and the resolution mediator cargo. With these future goals in mind, it is encouraging to note that NP therapeutics are now in clinical use or under clinical investigation for a myriad of other conditions including cancers (48) , vaccines (49) , and imaging (50) . Thus, our atheroprotective strategy that capitalizes on plaque targeting to deliver a proresolving mediator may hold promise to decreasing the incidence of acute coronary events in subjects at high risk for atherothrombotic disease.
MATERIALS AND METHODS

Study design
The aim of this study was to test the therapeutic efficacy of targeted NPs containing the proresolving peptide Ac2-26 in experimental atherosclerosis. Animal experiments were conducted in Ldlr −/− mice using protocols approved by the Columbia University Standing Committee on Animals. The treatment groups included vehicle control, free Ac2-26 peptide, NPs containing a scrambled Ac2-26 peptide, and NPs containing Ac2-26 peptide. Unless otherwise indicated, 8 to 10 animals per group were investigated and were randomly assigned to the study groups. The experimentalists were blinded to the identity of the study groups while assaying the multiple endpoints in this study.
Synthesis and NP formulation
Copolymers of poly[lactic-co-glycolic acid-b-poly(ethylene glycol)] (PLGA-PEG), with or without Col IV-binding peptide or Alexa 647-cadaverine, were synthesized according to previously published methods (22) (fig. S1D) . Briefly, the C terminus of 50:50 PLGA (Lactel, 43.4 kD) and the functional amino group of NH 2 -PEG (Laysan Bio Inc., 3400 daltons) were coupled using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) (Sigma-Aldrich). Activated PLGA-NHS was coupled to the heterobifunctional maleimide-PEG-hydroxy to yield PLGA-PEG-Mal. The Col IV peptide-conjugated targeting polymer was then synthesized by conjugating KLWVLPK peptide to PLGA-PEG-Mal via the free thiol of the C-terminal GGGC linker using maleimide chemistry. The product was purified and washed by precipitation in cold methanol. A fluorescent polymer was also synthesized by coupling carboxy-terminated PLGA to Alexa 647-cadaverine.
The polymer (3 mg) was mixed with 120 mg of Ac2-26 (AMV-SEFLKQAWFIENEEQEYVQTVK) (Tocris Bioscience) or scrambled control peptide (WLKQKFQESVEQIAYVMENATEFEV) (Mimotopes) and dissolved in acetonitrile. This solution was then added dropwise to 10 ml of nuclease-free water, stirred for 2 hours, and then passed through a sterile 0.45-mm syringe filter. The NPs were then centrifuged at 3000g for 20 min using an Amicon Ultra-15 centrifugal filter units (molecular weight cutoff, 100 kD; Sigma-Aldrich), washed with deionized water, resuspended in 1 ml of nuclease-free H 2 O, and then diluted with sterile saline before injection. The final composition of the fluorescently labeled Col IV-Ac2-26 NPs was 87% PLGA-PEG-COOH, 5% PLGA-PEG-Col IV peptide, 4% PLGA-Alexa 647, and 4% Ac2-26 (w/w).
Animals and diets
Male Ldlr −/− mice, 8 to 10 weeks old, were purchased from The Jackson Laboratory and placed on a Western-type diet (TD.88137, Harlan Teklad) for 12 weeks. After 12 weeks, the mice were continued on the Western diet for an additional 5 weeks and injected intravenously once per week during this period with 200 ml of the following: Col IVAc2-26 NPs or Col IV-scrambled peptide NPs (10 mg of peptide per injection and an equivalent polymer amount), free Ac2-26 (10 mg per injection), or sterile saline (vehicle control). All procedures were conducted in accordance with protocols approved by the Columbia University Standing Committee on Animals guidelines for animal care.
Atherosclerotic lesion analysis
For morphometric lesion analysis, sections were stained with Harris' H&E. Total lesion and necrotic areas were quantified as described previously (30) . For plaque necrosis, boundary lines were drawn around regions that were free of H&E staining, and area measurements were obtained using image analysis software. Collagen staining was performed using picrosirius red as per the manufacturer's instructions (Polysciences Inc.). Because fibrous cap thickness can vary throughout the lesions, these values were assessed by averaging the thickness in micrometers of the cap in three separate regions of the lesions (that is, one measurement for each of the shoulder regions and one measurement in the middle of the lesion) and then expressing as AU of cap thickness/ lesion area. Collagenase activity in lesions was assayed using the DQ Collagenase Assay Kit from Life Technologies according to the manufacturer's instructions. Collagenase was analyzed by calculating MFI per lesion using ImageJ software.
For detection of superoxide, the frozen lesion sections were incubated with 1 mM DHE for 20 min at 37°C and then washed twice with phosphate-buffered saline (29) . Sections were counterstained with DAPI and mounted with antifade reagent (ProLong Gold). For both collagenase and DHE procedures, images were taken on a Zeiss fluorescence microscope and analyzed using ImageJ software. For mitoOS measurements, frozen sections were stained sequentially at 4°C with anti- Mac3 LCM, RNA amplification, and RT-qPCR Aortic root sections were subjected to laser capture using a PALM LCM machine as described previously (51) . RNA was isolated using the RNeasy Micro Kit (Qiagen) and linearly amplified using the MessageAmp II aRNA Kit (Ambion). The purity of the RNA was estimated by measuring absorbance at 260 and 280 nm using a NanoDrop (Thermo Scientific), and RNA with an A 260/280 of >1.8 was used for complementary DNA (cDNA) synthesis. cDNA was synthesized using the SuperScript VILO cDNA Synthesis Kit (Invitrogen), and qPCR was conducted using a 7500 Real-Time PCR system (Applied Biosystems) and SYBR Green chemistry. The following specific primers were purchased from Qiagen: Acta2 (#QT00140119), Il10 (#QT00106169), and Col3a1 (#QT01055516).
Bone marrow transplantation
Eight-to 10-week-old male Ldlr −/− mice were lethally irradiated using a cesium g source at a dose of 1000 rads 4 to 6 hours before transplantation (30) . Bone marrow cells were collected from the femurs and tibias of donor WT and Fpr2 −/− mice by flushing with sterile medium and then injected intravenously into the recipient mice, as described previously (52) . All animal procedures used in this study followed Columbia University's institutional guidelines. Six weeks after bone marrow transplantation (at 14 weeks of age), Ldlr −/− mice were fed the Western diet and treated with NPs as above.
Statistics
All results are presented as means ± SEM. P values were calculated using the Student's t test or one-way ANOVA with post hoc Tukey analysis for normally distributed data. For nonnormally distributed data, the Mann-Whitney rank sum test was used. 
SUPPLEMENTARY MATERIALS
